Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.

Clark-Langone KM, Sangli C, Krishnakumar J, Watson D.

BMC Cancer. 2010 Dec 23;10:691. doi: 10.1186/1471-2407-10-691.

2.

Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.

Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, Jeong J, Wu J, Langone KC, Watson D.

Clin Chem. 2007 Jun;53(6):1084-91. Epub 2007 Apr 26.

3.

Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies.

Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, Watson D, Falzarano SM, Magi-Galluzzi C, Klein EA, Quale C.

BMC Genomics. 2013 Oct 8;14:690. doi: 10.1186/1471-2164-14-690.

4.
5.

Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.

Dobbe E, Gurney K, Kiekow S, Lafferty JS, Kolesar JM.

Am J Health Syst Pharm. 2008 Jan 1;65(1):23-8. Review.

PMID:
18159035
6.

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou JF, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V.

PLoS Med. 2013;10(5):e1001453. doi: 10.1371/journal.pmed.1001453. Epub 2013 May 21.

7.

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, Beaumont C, Clark-Langone KM, Yoshizawa CN, Lee M, Watson D, Shak S, Kerr DJ.

J Clin Oncol. 2011 Dec 10;29(35):4611-9. doi: 10.1200/JCO.2010.32.8732. Epub 2011 Nov 7.

8.

Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.

Chen C, Dhanda R, Tseng WY, Forsyth M, Patt DA.

J Oncol Pract. 2013 Jul;9(4):182-7. doi: 10.1200/JOP.2012.000638. Epub 2013 Feb 12.

9.

Analytical performance of a formalin-fixed paraffin-embedded tissue-based 634-probe prognostic assay for predicting outcome of patients with stage II colon cancer.

Plamadeala V, Huang S, McCreary SM, Reitze NJ, Ewing AL, Gabrin MJ, Bennett AE, Mulligan JM, Wilson CL, Wang D.

Appl Immunohistochem Mol Morphol. 2014 Apr;22(4):308-16. doi: 10.1097/PDM.0000000000000031.

PMID:
24717231
10.

RT-PCR-based gene expression profiling for cancer biomarker discovery from fixed, paraffin-embedded tissues.

Scott A, Ambannavar R, Jeong J, Liu ML, Cronin MT.

Methods Mol Biol. 2011;724:239-57. doi: 10.1007/978-1-61779-055-3_15.

PMID:
21370017
11.

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI.

Am J Surg. 2008 Oct;196(4):527-9. doi: 10.1016/j.amjsurg.2008.06.021.

PMID:
18809056
12.

The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.

Joh JE, Esposito NN, Kiluk JV, Laronga C, Lee MC, Loftus L, Soliman H, Boughey JC, Reynolds C, Lawton TJ, Acs PI, Gordan L, Acs G.

Oncologist. 2011;16(11):1520-6. doi: 10.1634/theoncologist.2011-0045. Epub 2011 Oct 20.

13.

Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.

Srivastava G, Renfro LA, Behrens RJ, Lopatin M, Chao C, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim G, Mazurczak M, Lee M, Alberts SR.

Oncologist. 2014 May;19(5):492-7. doi: 10.1634/theoncologist.2013-0401. Epub 2014 Apr 7.

14.

Biomarker discovery for colon cancer using a 761 gene RT-PCR assay.

Clark-Langone KM, Wu JY, Sangli C, Chen A, Snable JL, Nguyen A, Hackett JR, Baker J, Yothers G, Kim C, Cronin MT.

BMC Genomics. 2007 Aug 15;8:279.

15.

Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.

Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM.

J Clin Oncol. 2013 May 10;31(14):1775-81. doi: 10.1200/JCO.2012.45.1096. Epub 2013 Mar 25.

16.

Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.

Ross JS.

Adv Anat Pathol. 2009 Jul;16(4):204-15. doi: 10.1097/PAP.0b013e3181a9d4bf. Review.

PMID:
19546609
17.

Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the oncotype DX test.

Dvorak L, Dolan M, Fink J, Varghese L, Henriksen J, Gulbahce HE.

Appl Immunohistochem Mol Morphol. 2013 May;21(3):196-9. doi: 10.1097/PAI.0b013e3182632ff5.

PMID:
22914611
18.

Histopathologic variables predict Oncotype DX recurrence score.

Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R.

Mod Pathol. 2008 Oct;21(10):1255-61. doi: 10.1038/modpathol.2008.54.

19.

Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas.

Acs G, Kiluk J, Loftus L, Laronga C.

Mod Pathol. 2013 Nov;26(11):1451-60. doi: 10.1038/modpathol.2013.88. Epub 2013 Jun 7.

20.

Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.

Zhu X, Dent S, Paquet L, Zhang T, Graham N, Song X.

Eur J Cancer. 2014 Oct;50(15):2544-9. doi: 10.1016/j.ejca.2014.07.010. Epub 2014 Aug 13.

PMID:
25129366
Items per page

Supplemental Content

Write to the Help Desk